Taiwan. Pharmaceutical market overview

IPR in Taiwan is improving, although there still remain concerns over patent linkage and data protection of pharmaceuticals. In January 2009, the USTR removed Taiwan from its Special 301 Watch List of countries, attributing the move to the country’s progress on protection and enforcement of IPR. However, in the USTR’s latest Special 301 Report for 2011, the USA remains concerned with the policies of Taiwan, on issues related to innovation in the pharmaceutical sector and other aspects of healthcare goods and services. In June 2010, the American Chamber of Commerce in Taipei’s latest White Paper stated that Taiwan lacks an effective patent linkage system. Attempts are being made to improve the compatibility of Taiwanese IP with other countries, and in June 2010 Taiwan signed an IP agreement with China which will mean that IP will be recognized as valid in both countries, even if it is filed only in one.

Source: TECTURA
Powered by Blogger.